Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Ono Pharmaceutical Co Ltd | 67 |
| 2 | Fate Therapeutics Inc | 13 |
| 3 | Fuji Chemical Industries Co Ltd | 12 |
| 4 | Sankyo Co Ltd | 10 |
| 5 | Sanofi Pasteur Inc | 9 |
| 6 | Sanofi Vaccines US Inc | 9 |
| 7 | Asahi Kasei Pharma Corp | 7 |
| 8 | Sanofi Pasteur SA | 7 |
| 9 | SBI Pharmaceuticals Co Ltd | 6 |
| 10 | Sanwa Kagaku Kenkyusho Co Ltd | 6 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 184 |
| 2 | A61K | Medicinal preparations | 175 |
| 3 | C07D | Heterocyclic compounds | 109 |
| 4 | G01N | Investigating / analysing materials | 52 |
| 5 | C12N | Microorganisms, enzymes | 44 |
| 6 | Y02A | Climate change adaptation | 37 |
| 7 | C12P | Fermentation, enzyme processes | 17 |
| 8 | Y10T | Cross-reference (technical subjects) | 17 |
| 9 | Y10S | Cross-reference (legacy) | 16 |
| 10 | C07H | Sugars and derivatives | 15 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Process for preparing protoporphyrin disodium salt | 2003 | SHANGHAI JINCHI BIOLOGICAL PRODUCTS CO., LTD. | 3 |
| PRODUCTION OF PROTOPORPHYRIN DISODIUM SALT | 1988 | SSP Co Ltd | 2 |
| A kind of preparation method of protoporphyrin disodium | 2018 | HUAZHONG AGRICULTURAL UNIVERSITY | 0 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Photodynamic Therapy Research Studies | 31 |
| 2 | Nanoplatforms for cancer theranostics | 7 |
| 3 | Heme Oxygenase-1 and Carbon Monoxide | 6 |
| 4 | Porphyrin Metabolism and Disorders | 6 |
| 5 | Porphyrin and Phthalocyanine Chemistry | 3 |
| 6 | Hemoglobin structure and function | 2 |
| 7 | Advanced Fluorescence Microscopy Techniques | 1 |
| 8 | Click Chemistry and Applications | 1 |
| 9 | DNA Repair Mechanisms | 1 |
| 10 | Dermatologic Treatments and Research | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Johan Moan | Norwegian Cancer Society | 50 |
| 2 | Tayyaba Hasan | Massachusetts General Hospital | 24 |
| 3 | Asta Juzeniene | Norwegian Cancer Society | 19 |
| 4 | Hans Christian Wulf | Bispebjerg Hospital | 19 |
| 5 | Alexander J. MacRobert | University College London | 17 |
| 6 | Pan Wang | Shaanxi Normal University | 16 |
| 7 | Petras Juzenas | Norwegian Cancer Society | 16 |
| 8 | Brian W. Pogue | Dartmouth College | 15 |
| 9 | Norbert Lange | École Polytechnique Fédérale de Lausanne | 15 |
| 10 | Qian Peng | Oslo University Hospital | 14 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Photodynamic therapy with endogenous protoporphyrin | 1990 | 1527 | Photodynamic Therapy Research Studies |
| The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria | 2002 | 822 | Drug Transport and Resistance Mechanisms |
| 5‐Aminolevulinic Acid‐Based Photodynamic Therapy: Principles and Experimental Research | 1997 | 621 | Nanoplatforms for cancer theranostics |
| Chloroplast to nucleus communication triggered by accumulation of Mg-protoporphyrinIX | 2003 | 592 | Plant Molecular Biology Research |
| Graphene as a Substrate To Suppress Fluorescence in Resonance Raman Spectroscopy | 2009 | 527 | Gold and Silver Nanoparticles Synthesis and Applications |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of Protoporphyrin disodium?
Which organizations hold the most patents for Protoporphyrin disodium?
What are the main research topics associated with Protoporphyrin disodium?
Who are the most prolific authors publishing on Protoporphyrin disodium?
What is the coverage of Protoporphyrin disodium in the scientific and patent literature?